v3.24.0.1
Consolidated Statements of Operations - USD ($)
 12 Months Ended
Dec. 31, 2023
Dec. 31, 2022
Income Statement [Abstract]    
Federal grants $ 2,230,520 $ 2,523,383
Operating expenses:    
Research and development 7,587,473 19,835,875
General and administrative 5,361,234 6,909,603
Total operating expenses 12,948,707 26,745,478
Loss from operations (10,718,187) (24,222,095)
Other income (expense):    
Loss on issuance of convertible notes (3,609,944)
Issuance costs for convertible notes (1,137,740)
Loss on conversions and change in fair value of convertible notes 146,479 1,792,154
Issuance of liability classified warrants (3,737,371)
Change in fair value of liability classified warrants 283,958 6,730,613
Interest expense, net (353,945) (109,525)
Other income and expense, net 15,420 86,223
Total other income (expense), net 91,912 14,410
Net loss (10,626,275) (24,207,685)
Net loss attributable to noncontrolling interests (13,201) (35,393)
Deemed dividend related to warrants down round provision 12,937 913,204
Net loss attributable to common stockholders $ (10,626,011) $ (25,085,496)
Net loss per basic and diluted share:    
Net loss per share attributable to common stockholders, basic $ (4.69) $ (139.42)
Net loss per share attributable to common stockholders, diluted $ (4.69) $ (139.42)
Weighted average common shares outstanding, basic 2,264,060 179,925
Weighted average common shares outstanding, diluted 2,264,060 179,925

Source

PDF HTML
ZIP XLS XBRL